BackEiger BioPharmaceuticals Overview

Eiger BioPharmaceuticals Receivables

Eiger BioPharmaceuticals's receivables is $1.7M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$1.68M
↓ 3.83% YoYΔ $-67000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Eiger BioPharmaceuticals Receivables History

Loading

Eiger BioPharmaceuticals vs. peers: Receivables Comparison

Loading

Eiger BioPharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Eiger BioPharmaceuticals (EIGR) FAQ

As of the most recent data (December 2023), EIGR shows a receivables of $1.7M. That compares with $1.7M in the prior-year period — down 3.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EIGR's receivables is now $1.7M (was $1.7M) — a 3.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Eiger BioPharmaceuticals is outperforming or lagging.

Tracking EIGR's receivables over time shows whether Eiger BioPharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $1.7M That compares with $1.7M in the prior-year period — down 3.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Eiger BioPharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $1.7M) with ownership activity and broader fundamentals.

Eiger BioPharmaceuticals's receivables is $1.7M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.